Showing 7221-7230 of 7612 results for "".
- Promising Data Presented for Viviscal Oral Supplement to Promote Hair Growthhttps://practicaldermatology.com/news/20130625-promising_data_presented_for_viviscal_oral_supplement_to_promote_hair_growth/2459510/An office-dispensed oral food supplement appears to promote existing hair growth for women suffering from temporary thinning hair, according to data presented at the World Hair Congress in Edinburgh, Scotland this spring. Subjects treated with Viviscal Hair Nourishment System
- Phase III Data Show Galderma's Topical Redness Reducer is Effective, Safehttps://practicaldermatology.com/news/20130625-phase_iii_data_show_galdermas_topical_redness_reducer_is_effective_safe/2459511/Topical brimonidine tartrate gel 0.5% is safe and effective for the management of erythema of rosacea, with benefit evidence as early as 30 minutes after application, new data show. (JDD, 12(6):650-656) Data from two identically designed randomized, double-blind, vehicle controlled phase III trials
- "Parasols of Protection" Highlights UV Safetyhttps://practicaldermatology.com/news/20130624-parasols_of_protection_highlights_uv_safety/2459512/Kicking off the summer with an educational sun protection campaign, the Women's Dermatologic Society (WDS), Duane Reade, and La Roche-Posay's Parasols of Protection event raised awareness about skin cancer through a
- Artefill Shows Efficacy for Atrophic Acne Scars: Datahttps://practicaldermatology.com/news/20130624-artefill_shows_efficacy_for_atrophic_acne_scars_data/2459513/Recently reported data suggest that ArteFill dermal filler is an effective option to treat atrophic acne scars. Suneva Medical shared promising six-month results from its randomized, double-blinded, multi-center, controlled study that evaluated the
- Stelara Approved for Self-Administrationhttps://practicaldermatology.com/news/20130611-stelara_approved_for_self-administration/2459518/The FDA has approved Stelara (ustekinumab) for self-administration. Previously intended for subcutaneous administration under the supervision of a physician, Stelara can now be administered by patients at home. The drug is approved for the treatment of adult patients with moderate to severe plaque p
- National Psoriasis Foundation Awards Research Grantshttps://practicaldermatology.com/news/20130610-national_psoriasis_foundation_awards_research_grants/2459519/Six scientists received National Psoriasis Foundation (NPF) research grants totaling $450,000 for projects that aim to discover new treatments and a cure for psoriasis and psoriatic arthritis. Theoharis Theoharides, MD, PhD received a
- Jurlique Product Supports the Underservedhttps://practicaldermatology.com/news/20130607-jurlique_product_supports_the_underserved/2459521/The Jurlique Ideas of Beauty Fund by Jurlique and Chrysalis supports the empowerment of women to lead better lives. Through the fund, Jurlique donates to organizations around the world committed to helping women. Proceeds from every
- Levia Targeted Phototherapy Now Part of Daavlinhttps://practicaldermatology.com/news/20130531-levia_targeted_phototherapy_now_part_of_daavlin/2459525/Daavlin has been appointed by Lerner Medical Devices to exclusively manufacture, sell, and support their Levia Targeted Home Phototherapy Device. The Levia device complements Daavlin's line of home units for the treatment of skin disorders such as psoriasis, vitiligo, and eczema. Product warranties
- New Technical Manager at Jurliquehttps://practicaldermatology.com/news/20130531-new_technical_manager_at_jurlique/2459527/Jurlique appointed Connie Lim to Technical Manager of Global Product Development. In her new role, Ms. Lim will drive innovative formula development, provide technical support, and monitor performance and key milestones in global new product development efforts. Ms. Lim comes to Jurlique with mor
- Two Melanoma Drugs Win FDA Approvalhttps://practicaldermatology.com/news/20130530-two_melanoma_drugs_win_fda_approval/2459528/The FDA approved two new drugs for metastatic or inoperable melanoma, dabrafenib (Tafinlar) and trametinib (Mekinist). Dabrafenib is an inhibitor of the BRAF gene when it carries the so-called V600E mutation. Trametinib inhibits a target known as MEK and is effective primarily against melanomas carr